8-K filed Aug 4, 2026 at 07:20 ET
Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where stockholders approved all six proposals, including an amendment to increase the 2020 Stock Incentive Plan share pool from 4,500,000 to 6,500,000 shares, an increase in authorized common shares, and the issuance of common stock upon warrant exercise. The filing is a routine post-meeting report with no financial results or material corporate events, the increased share authorization and warrant issuance approval signal potential future dilution, but no immediate action has been taken. For a $10M market cap micro-cap, the approval of a 44% increase in the equity incentive pool and a broad authorized share increase is a modestly bearish signal for existing holders, as it enables future dilution without any current operational catalyst to offset it.